Janux Therapeutics, Inc. JANX

US Biotechnology

$12.23 ▼ -4.15% ($-0.53)

📉 Near 52W Low ⬇️ Below Yest. Low 🎢 High Beta

Open $12.90

Prev Close $12.76

Day Range $11.59 – $12.91

52W Range $12.12 – $35.34

Market Cap $780.70M

Beta 2.47

EPS (TTM) $-1.64

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-06-11
Shares Out.	61,140,000
Website	januxrx.com/ ↗
Phone	13026587581
Employees	114
Revenue	$10.3M
Gross Profit	$10.3M
Net Income	-$22.0M
Free Cash Flow	-$41.9M
Total Assets	$1.01B
Total Liabilities	$79.7M
Equity	$928.0M

About Janux Therapeutics, Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Janux Therapeutics, Inc. is a publicly traded company under the ticker symbol JANX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.